Globus Medical, Inc. (GMED) P/E Ratio History
Deep ValueTrading at 20.2x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2012–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, Globus Medical, Inc. (GMED) trades at a price-to-earnings ratio of 20.2x, with a stock price of $79.23 and trailing twelve-month earnings per share of $4.25.
The current P/E is 64% below its 5-year average of 55.7x. Over the past five years, GMED's P/E has ranged from a low of 18.5x to a high of 231.3x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, GMED is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
The PEG ratio of 0.65 (P/E divided by 423% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, GMED trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GMED DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GMED Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
GMED P/E vs Peers
Orthopedics, spine, and sports medicine peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $118B | 36.6 | 2.46 | +8% | |
| $17B | 24.8 | - | -20% | |
| $62M | 14.7Lowest | - | +125%Best | |
| $102B | 22.0 | - | +31% | |
| $67B | 23.3 | - | +55% | |
| $17B | 30.5 | - | -25% | |
| $144B | 51.7 | 2.37Best | +23% | |
| $4B | 31.6 | - | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
GMED Historical P/E Data (2012–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $86.16 | $4.28 | 20.1x | -49% |
| FY2025 Q4 | Dec 31 2025 | $87.31 | $3.92 | 22.3x | -44% |
| FY2025 Q3 | - | $57.27 | $3.10 | 18.5x | -54% |
| FY2025 Q2 | Jun 30 2025 | $59.02 | $2.60 | 22.7x | -43% |
| FY2025 Q1 | Mar 31 2025 | $73.20 | $1.34 | 54.6x | +37% |
| FY2024 Q4 | - | $82.71 | $0.75 | 110.7x | +178% |
| FY2024 Q3 | Sep 30 2024 | $71.54 | $0.67 | 107.2x | +169% |
| FY2024 Q2 | Jun 30 2024 | $68.49 | $0.30 | 231.3x | +481% |
| FY2024 Q1 | Mar 31 2024 | $53.64 | $0.64 | 84.3x | +112% |
| FY2023 Q4 | Dec 31 2023 | $53.29 | $1.17 | 45.6x | +15% |
| FY2023 Q3 | Sep 30 2023 | $49.65 | $1.55 | 32.1x | -19% |
| FY2023 Q2 | Jun 30 2023 | $59.54 | $2.01 | 29.6x | -26% |
| FY2023 Q1 | Mar 31 2023 | $56.64 | $1.97 | 28.8x | -28% |
| FY2022 Q4 | Dec 31 2022 | $74.27 | $1.86 | 39.9x | +0% |
| FY2022 Q3 | Sep 30 2022 | $59.57 | $1.51 | 39.5x | -1% |
| FY2022 Q2 | - | $56.14 | $1.49 | 37.7x | -5% |
| FY2022 Q1 | - | $73.78 | $1.36 | 54.3x | +36% |
| FY2021 Q4 | Dec 31 2021 | $72.20 | $1.43 | 50.5x | +27% |
| FY2021 Q3 | - | $76.62 | $1.81 | 42.3x | +6% |
| FY2021 Q2 | Jun 30 2021 | $77.53 | $1.80 | 43.1x | +8% |
| FY2021 Q1 | Mar 31 2021 | $61.67 | $1.19 | 51.8x | +30% |
| FY2020 Q4 | - | $65.22 | $1.00 | 65.2x | +64% |
| FY2020 Q3 | Sep 30 2020 | $49.52 | $0.92 | 53.8x | +35% |
| FY2020 Q2 | - | $47.71 | $0.86 | 55.5x | +39% |
| FY2020 Q1 | - | $42.53 | $1.45 | 29.3x | -26% |
| FY2019 Q4 | - | $58.88 | $1.53 | 38.5x | -3% |
| FY2019 Q3 | Sep 30 2019 | $51.12 | $1.45 | 35.3x | -11% |
| FY2019 Q2 | Jun 30 2019 | $42.30 | $1.42 | 29.8x | -25% |
| FY2019 Q1 | Mar 31 2019 | $49.41 | $1.48 | 33.4x | -16% |
| FY2018 Q4 | Dec 31 2018 | $43.28 | $1.54 | 28.1x | -29% |
| FY2018 Q3 | Sep 30 2018 | $56.76 | $1.43 | 39.7x | -0% |
| FY2018 Q2 | Jun 30 2018 | $50.46 | $1.34 | 37.7x | -5% |
| FY2018 Q1 | Mar 31 2018 | $49.82 | $1.19 | 41.9x | +5% |
| FY2017 Q4 | Dec 31 2017 | $41.10 | $1.10 | 37.4x | -6% |
| FY2017 Q3 | Sep 30 2017 | $29.72 | $1.10 | 27.0x | -32% |
| FY2017 Q2 | Jun 30 2017 | $33.15 | $1.11 | 29.9x | -25% |
| FY2017 Q1 | Mar 31 2017 | $29.62 | $1.09 | 27.2x | -32% |
| FY2016 Q4 | Dec 31 2016 | $24.81 | $1.08 | 23.0x | -42% |
| FY2016 Q3 | Sep 30 2016 | $22.57 | $1.22 | 18.5x | -54% |
| FY2016 Q2 | - | $23.83 | $1.23 | 19.4x | -51% |
| FY2016 Q1 | - | $23.75 | $1.21 | 19.6x | -51% |
| FY2015 Q4 | - | $27.82 | $1.18 | 23.6x | -41% |
| FY2015 Q3 | Sep 30 2015 | $20.66 | $1.08 | 19.1x | -52% |
| FY2015 Q2 | - | $25.67 | $1.04 | 24.7x | -38% |
| FY2015 Q1 | - | $25.24 | $1.01 | 25.0x | -37% |
| FY2014 Q4 | Dec 31 2014 | $23.77 | $0.97 | 24.5x | -38% |
| FY2014 Q3 | - | $19.67 | $0.90 | 21.9x | -45% |
| FY2014 Q2 | Jun 30 2014 | $23.92 | $0.88 | 27.2x | -32% |
| FY2014 Q1 | Mar 31 2014 | $26.59 | $0.74 | 35.9x | -10% |
| FY2013 Q4 | - | $20.18 | $0.73 | 27.6x | -31% |
| FY2013 Q3 | Sep 30 2013 | $17.46 | $0.73 | 23.9x | -40% |
| FY2013 Q2 | Jun 30 2013 | $16.86 | $0.69 | 24.4x | -39% |
| FY2013 Q1 | Mar 31 2013 | $14.68 | $0.82 | 17.9x | -55% |
| FY2012 Q4 | Dec 31 2012 | $10.49 | $0.84 | 12.5x | -69% |
| FY2012 Q3 | Sep 30 2012 | $18.03 | $0.77 | 23.4x | -41% |
Average P/E for displayed period: 39.8x
Full Stock Analysis
Deep dive into GMED consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GMED — Frequently Asked Questions
Quick answers to the most common questions about buying GMED stock.
What is GMED's P/E ratio?
Globus Medical, Inc. (GMED) trailing twelve-month P/E ratio is 20.2x, based on TTM diluted EPS of $4.25. The 5-year average P/E is 55.7x and the historical range spans 18.5x to 231.3x.
Is GMED stock overvalued or undervalued?
GMED trades at 20.2x P/E, below its 5-year average of 55.7x. At the 10th percentile of its historical range (18.5x–231.3x), the stock is priced at a discount to its own history.
Is GMED stock expensive?
No, GMED is not expensive on a historical basis. The current P/E of 20.2x is below the 5-year average of 55.7x and sits at the 10th percentile of its valuation range.
What is GMED's historical P/E range?
Over the past 5 years, GMED's P/E ratio has ranged from 18.5x to 231.3x, with a median of 42.3x and an average of 55.7x. The current P/E of 20.2x places the stock at the 10th percentile of this range. Full historical data spans 2012–2026.
How does GMED's P/E compare to the S&P 500?
GMED trades at 20.2x P/E versus the S&P 500 median of 24.4x. The 17% discount to the market suggests lower growth expectations or perceived higher risk.
How does GMED's valuation compare to Healthcare peers?
Globus Medical, Inc. P/E of 20.2x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is GMED's PEG ratio?
GMED PEG ratio is 0.65, based on a P/E of 20.2x and EPS growth of 422.7%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.
What is GMED's earnings yield?
GMED earnings yield is 4.95%, the inverse of its 20.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.